For patients with DCIS, risk of death higher for women under 35, black women
the ONA take:
Women diagnosed with ductal carcinoma in situ have a 20-year breast cancer-specific death rate of 3.3%, with a higher death rate among women diagnosed before age 35 and black women, according to a study published online ahead of print in JAMA Oncology.
For the study, researchers analyzed data from 108,196 women diagnosed with ductal carcinoma in situ of the breast included in the Surveillance, Epidemiology and End Results (SEER) database and compared their risk of dying of breast cancer with that of women in the general population.
Results showed that the 10-year breast cancer-specific death rate after cancer diagnosis was 1.1% and the 20-year rate was 3.3%. Researchers found that women who had a ductal carcinoma in situ diagnosis have a 1.8 times higher risk of death compared those in the general population.
The study also demonstrated that age at diagnosis and black ethnicity were risk factors for death following a ductal carcinoma in situ diagnosis.
Women diagnosed with ductal carcinoma in situ have a 20-year breast cancer-specific death rate of 3.3%.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Exercise Improves Coping While Undergoing Chemotherapy for Advanced GI Cancer
- Genetic Similarity to BRCA1/BRCA2 Mutations May Impact Treatment Options
- Evidenced-Based Radiation Treatment Tied to Cost Savings in Early Stage Breast Cancer
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|